Andrew Nixon

This inventor holds 22 USPTO granted patents and 12 published patent applications, plus 2 CIPO patents and 8 EPO patents. Top assignees: Takeda Pharmaceutical Company Limited, Dyax Corporation, Athera Biotechnologies Ab. Active years: 2007-2025.

USPTO Granted Patents = 22 (Patent Applications = 12)

% Patents Active = 90.9

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 8 (Patent Applications = 17)

Average Co-Inventor Count = 3.9

ph-index = 6

Forward Citations = 118(Granted Patents)

Company Filing History:

11 out of 1,226

Takeda Pharmaceutical Company Limited

Athera Biotechnologies Ab

patents

4. 2 out of 15

Magenta Therapeutics, Inc.

patents

where one patent can have more than one assignee

Years Active: 2007-2025

Loading Chart...

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12442824 - Assays for determining plasma kallikrein system biomarkers (2025-10-14),

2. 12415866 - Monoclonal antibody inhibitor of Factor XIIa (2025-09-16),

3. 12240918 - Bispecific antibodies against plasma kallikrein and factor XII (2025-03-04),

4. 12110343 - Anti-plasma kallikrein antibodies (2024-10-08),

5. 12084515 - Compositions and methods for treatment of diabetic macular edema (2024-09-10),

6. 12061206 - Diagnosis and treatment of autoimmune diseases (2024-08-13),

7. 11390687 - Bispecific antibodies against plasma kallikrein and Factor XII (2022-07-19),

8. 11372002 - Assays for determining plasma kallikrein system biomarkers (2022-06-28),

9. 11299553 - Anti-plasma kallikrein antibodies (2022-04-12),

10. 11156612 - Methods of determining levels of cleaved and/or intact kininogen (2021-10-26),

11. 11046785 - Compositions and methods for treatment of diabetic macular edema (2021-06-29),

12. 10913802 - Monoclonal antibody inhibitor of factor XIIA (2021-02-09),

13. 10648990 - Diagnosis and treatment of autoimmune diseases (2020-05-12),

14. 10624973 - Methods for the depletion of cells (2020-04-21),

15. 10428158 - Compositions and methods for treatment of diabetic macular edema (2019-10-01),

Title: Andrew Nixon - Innovator in Biopharmaceuticals

Introduction

Andrew Nixon, based in Hanover, MA, has made significant contributions to the field of biopharmaceuticals, holding a remarkable 20 patents to his name. His innovative work primarily focuses on developing therapies that target critical components of the contact system in the human body.

Latest Patents

Among his most notable patents are those related to bispecific antibodies that target plasma kallikrein and Factor XII. These patents describe antibodies designed to treat diseases such as hereditary angioedema and thrombosis. Additionally, he has developed antibodies that bind to plasma kallikrein, effectively inhibiting its activity and providing therapeutic benefits by interacting with specific residues within the protein's catalytic domain.

Career Highlights

Andrew Nixon’s career has included notable tenures at recognized companies such as Dyax Corporation and Takeda Pharmaceutical Company Limited. His expertise in antibody development has positioned him as a leading innovator in the biopharmaceutical sector, contributing to advancements in medical science.

Collaborations

Throughout his career, Andrew has worked alongside esteemed colleagues, including Daniel J. Sexton and Burt Adelman. These collaborations have further enriched the scope of his research and the impact of his contributions to the field.

Conclusion

With a portfolio of 20 patents, Andrew Nixon is a noteworthy inventor whose work in developing bispecific antibodies holds promise for treating complex medical conditions. His dedication to innovation in biopharmaceuticals continues to shape the future of therapeutic interventions.